Biotechnology - Rare diseases, Pharmaceutical

Filter

Popular Filters

1 to 25 of 71 results

SOBI restructures Kineret and Kepivance deals

09-09-2013

Swedish Orphan Biovitrum (STO: SOBI) said this morning that it has acquired the full rights to develop…

AmgenAnti-Arthritics/RheumaticsBiotechnologyKepivanceKineretLicensingOncologyPharmaceuticalRare diseasesSwedish Orphan Biovitrum

Kyowa Hakko Kirin collaborates with Ultragenyx on KRN23

06-09-2013

Japanese mid-sized drugmaker Kyowa Hakko Kirin (TYO: 4151) has entered into a collaboration and license…

BiotechnologyKRN23Kyowa Hakko KirinLicensingPharmaceuticalRare diseasesResearchUltragenyx

Chiesi expands rare disease portfolio with acquisition

26-08-2013

Privately-owned Italian drugmaker Chiesi Group has signed, through its UK affiliate, a definitive agreement…

BiotechnologyChiesi FarmaceuticiLamazymMergers & AcquisitionsPharmaceuticalRare diseasesZymenex

Shire and Santaris extend strategic alliance

23-08-2013

Danish privately held clinical-stage biopharmaceutical company Santaris Pharma says that its long term…

BiotechnologyLicensingPharmaceuticalRare diseasesResearchSantaris PharmaShire

New Zealand to widen access for type 1 and type 3 Gaucher disease drug

07-08-2013

New Zealand's Pharmaceutical Management Agency PHARMAC has announced the approval of a proposal to widen…

Asia-PacificBiotechnologyCerezymeGenzymePharmaceuticalRare diseasesRegulationSanofi

Aegerion gains European approval for rare disease drug

05-08-2013

The European Commission has approved US biopharma company Aegerion Pharmaceuticals' (Nasdaq: AEGR) Lojuxta…

Aegerion PharmaceuticalsBiotechnologyCardio-vascularEuropeJuxtapidKynamroLojuxtalomitapidePharmaceuticalRare diseasesRegulation

UK's NICE calls for more data to consider Roche drug for a type of vasculitis

23-07-2013

UK drug watchdog the National Institute for Health and Care Excellence (NICE) has today (July 23) published…

BiotechnologyEuropeMabTheraOncologyPharmaceuticalPricingRare diseasesRegulationRoche

Deal between Ensemble and Alexion will target ultra-rare disorders

18-07-2013

USA-based drug discovery firm Ensemble Therapeutics has announced the initiation of a drug discovery…

Alexion PharmaceuticalsBiotechnologyEnsemble TherapeuticsNorth AmericaPharmaceuticalRare diseasesResearch

Orphan status for Alexion's Solaris

16-07-2013

US drugmaker Alexion Pharmaceuticals (Nasdaq: ALXN) says that Soliris (eculizumab), the company's first-in-class…

Alexion PharmaceuticalsBiotechnologyEuropeNeurologicalPharmaceuticalRare diseasesRegulationSolaris

Lupus therapeutics boast blockbuster hopefuls as R&D continues, says GlobalData

24-06-2013

Lupus therapeutics are lacking, and patients with moderate forms of the disease are greatly underserved,…

BenlystaBiotechnologyBristol-Myers SquibbepratuzumabGlaxoSmithKlineImmunologicalsMarkets & MarketingOrenciaPharmaceuticalRare diseasesResearchUCB

European Medicines Agency simplifies processing of fee reductions for orphan medicines

09-05-2013

The European Medicines Agency has cancelled the procedure by which sponsors of medicines with an orphan…

BiotechnologyEuropeFinancialPharmaceuticalRare diseasesRegulation

MoCA report a welcome stepping stone, but access to orphan medicines remains unfinished business, say trade groups

09-05-2013

The three leading pharma/biotech trade bodies, EuropaBio, the European Federation of Pharmaceutical Industries…

BiotechnologyEuropeHealthcarePharmaceuticalPoliticsRare diseasesRegulation

Acceleron and Shire not to restart ACE-031 program

03-05-2013

Privately-held US biotech firm Acceleron Pharma says that Ireland-headquartered Shire (LSE: SHP) has…

Acceleron PharmaACE-031BiotechnologyLicensingPharmaceuticalRare diseasesResearchShire

Orphan diseases' appeal lies in return on investment, says Evaluate

24-04-2013

For many years, Big Pharma's model of success has been the blockbuster: drugs that sell more than $1…

BiotechnologyFinancialMarkets & MarketingPharmaceuticalRare diseasesResearch

Merck Serono's EPP funds EspeRare Foundation, which will reposition rimeporide

15-04-2013

Merck Serono, the biotech unit of Germany's Merck KGaA (MRK: DE) has announced the launch of the EspeRare…

BiotechnologyEspeRare FoundationFinancialMerck KGaAMerck SeronoPharmaceuticalRare diseasesResearchrimeporide

Pfizer and Protalix' Gaucher drug Uplyso approved in Brazil

19-03-2013

US drugs behemoth Pfizer (NYSE: PFE) and Israel-based Protalix BioTherapeutics (NYSE MKT:PLX) said that…

BiotechnologyElelysoPfizerPharmaceuticalProtalix BioTherapeuticsRare diseasesRegulationSouth AmericaUplyso

Shire acquires Premacure to expand in new therapy area

13-03-2013

In a second acquisition so far this year, Ireland-headquartered drugmaker Shire (LSE: SHP) said on Tuesday…

BiotechnologyMergers & AcquisitionsOphthalmicsPharmaceuticalPremacureRare diseasesShire

Rare diseases research gets 144 million-euro funding from European Commission

01-03-2013

On Rare Disease Day 2013 (February 28), the European Commission announced 144 million euros ($189.5 million)…

BiotechnologyEuropeFinancialPharmaceuticalRare diseasesResearch

Global orphan drugs market led by Roche's rituximab

26-02-2013

The global orphan drugs market is estimated to have increased at a compound annual growth rate (CAGR)…

BiotechnologyLucentisMarkets & MarketingNovartisPharmaceuticalRare diseasesRituxanRoche

Genzyme's eliglustat meets endpoints in Ph III studies for Gaucher disease

18-02-2013

US biotech firm Genzyme, a subsidiary if French drug major Sanofi (Euronext: SAN) has released positive…

BiotechnologyeliglustatGenzymePharmaceuticalRare diseasesResearchSanofi

EMA Committee for Orphan Medicinal Products - strengthened interactions with patients and international partners

17-02-2013

"The European Medicines Agency's Committee for Orphan Medicinal Products (COMP) is stepping into another…

BiotechnologyEuropePharmaceuticalRare diseasesRegulation

Regulatory news for Hyperion's Ravicti and Seattle Genetics' Adcetris

04-02-2013

The US Food and Drug Administration on Friday approved Hyperion Therapeutics' (Nasdaq: HPTX) Ravicti…

AdcetrisBiotechnologyHyperion TherapeuticsNorth AmericaOncologyPatentsPharmaceuticalRare diseasesRavictiRegulationSeattle Genetics

FDA clears Sanofi and Isis' Kynamro for inherited cholesterol disorder

30-01-2013

The US Food and Drug Administration yesterday approved Sanofi (Euronext: SAN) subsidiary Genzyme's orphan…

BiotechnologyCardio-vascularGenzymeIsis PharmaceuticalsKynamroNorth AmericaPharmaceuticalRare diseasesRegulationSanofi

1 to 25 of 71 results

Back to top